Terms of Use

Effective Date: February 24, 2026

Pelage Pharmaceuticals, Inc.

 

Welcome to the Pelage Pharmaceuticals, Inc. website (the “Site”). These Terms of Use (“Terms”) govern your access to and use of our Site and services (collectively, the “Service”). By accessing or using the Service, you agree to be bound by these Terms and our Privacy Policy. If you do not agree to these Terms, please discontinue use of the Service immediately.

1. No Medical Advice

The content on this Site, including information regarding PP405 and regenerative medicine for hair loss, is provided for informational purposes only. Pelage Pharmaceuticals, Inc. (“Pelage”) does not provide medical advice, diagnosis, or treatment.

  • Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.

  • PP405 is currently an investigational drug in Phase 2 clinical trials and has not yet been approved by the FDA for commercial sale.

  • Clinical trial information provided on the Site (NCT06393) is subject to change and does not guarantee eligibility or results.

2. Intellectual Property Rights

All content on this Site, including text, graphics, logos, scientific publications, and software, is the property of Pelage or its content suppliers and is protected by United States and international copyright and trademark laws.

  • You may not reproduce, distribute, or create derivative works from this content without express written permission from Pelage.

  • The discovery of the metabolic switch in hair follicles and related scientific findings are proprietary assets of Pelage and its partners (e.g., UCLA).

3. Permitted Use

You agree to use the Service only for lawful purposes. You are prohibited from:

  • Using the Service in any way that violates applicable federal, state, or international law.

  • Attempting to interfere with the proper working of the Site or bypassing any security measures.

  • Engaging in data mining, robots, or similar data gathering and extraction tools.

4. Third-Party Links

For your convenience, our Site may contain links to third-party websites, such as clinical trial registries or news outlets. Pelage has no control over these sites and is not responsible for their content or privacy practices.

5. Disclaimer of Warranties

The Service is provided on an “AS IS” and “AS AVAILABLE” basis. Pelage makes no representations or warranties of any kind, express or implied, as to the operation of the Service or the information, content, or materials included on this Site.

6. Limitation of Liability

To the fullest extent permitted by law, Pelage Pharmaceuticals, Inc. shall not be liable for any damages of any kind arising from the use of the Service, including but not limited to direct, indirect, incidental, punitive, and consequential damages.

7. Governing Law

These Terms are governed by and construed in accordance with the laws of the United States and the State where Pelage is headquartered, without regard to its conflict of law principles.

8. Changes to These Terms

Pelage reserves the right to update or modify these Terms at any time. We will notify you of any material changes by revising the “Effective Date” at the top of this page.

9. Contact Information

If you have any questions about these Terms, please contact us:

  • General Inquiries: info@pelagepharma.com

  • Press Inquiries: media@pelagepharma.com

Clinical Advisory Board

Arash Mostaghimi, M.D., M.P.A., M.P.H., F.A.A.D.

Vice Chair of Clinical Trials and Innovation, Director of the Dermatology Inpatient Service at Brigham & Women’s Hospital
Associate Professor of Dermatology, Harvard Medical School

Dr. Arash Mostaghimi is the Vice Chair of Clinical Trials and Innovation and Director of the Consult Service for the Department of Dermatology at Brigham & Women’s Hospital.  With board certifications in dermatology, internal medicine, and clinical informatics, Dr. Mostaghimi is an active clinician with an emphasis on complex medical dermatology and hair loss disorders.  As a clinical researcher, Dr. Mostaghimi has over 275 peer reviewed publication, and served as a principal investigator involved in the design and implementation of numerous clinical trials. He has received numerous teaching and mentorship awards and is co-director of the Complex Medical Dermatology Fellowship.

Clinical Advisory Board

Amy McMichael, M.D., F.A.A.D.

Professor and Past Chair of Dermatology, Wake Forest School of Medicine

Dr. Amy McMichael is a Philadelphia native who received her medical degree from the University of Pennsylvania School of Medicine. She completed Dermatology residency training at the University of Michigan School of Medicine.

Dr. McMichael is a Professor in the Department of Dermatology at Wake Forest School of Medicine in Winston-Salem, NC. She has held leadership positions in the Department for over 20 years first as Residency Program Director for 12 years and Chair of the Department for 11 years. She has been a leader in her field, including her roles as past President of Skin of Color Society and past President of the National Medical Association Dermatology Section. She recently served as a Board member of the American Academy of Dermatology.
Dr. McMichael’s clinical and research interests include: hair and scalp disorders, psoriasis, and skin of color. She is co-editor of several medical

Clinical Advisory Board

Mathew Avram, M.D., J.D., F.A.A.D.

Director of the Dermatology Laser & Cosmetic Center, Massachusetts General Hospital
Associate Professor of Dermatology, Harvard Medical School

Dr. Mathew M. Avram is the Director of the Massachusetts General Hospital Dermatology Laser & Cosmetic Center and serves as Faculty Director for Dermatology Cosmetic Training at Harvard Medical School. He is the Past-President of both the American Society for Dermatologic Surgery and American Society for Laser Medicine & Surgery. Dr. Avram has co-authored 7 textbooks and 90 peer-reviewed publications. Dr. Avram has delivered over 800 invited lectures, co-chaired teaching sessions for the FDA for three years, and has two U.S. patents. Dr. Avram has been recognized by Newsweek as one of the Top 10 cosmetic dermatologists in America.

Clinical Advisory Board

Amelia K. Hausauer, M.D., F.A.A.D.

Director of Dermatology and Minimally Invasive Aesthetics at Aesthetx

Dr. Amelia K. Hausauer is the Director of Dermatology and Head of Aesthetic Medicine at Aesthetx, a hybrid dermatology and plastic surgery practice in Northern California. She is a key opinion leader for early pipeline innovation and development of multiple injectable and regenerative therapies as well as an active research investigator. Dr. Hausauer spearheaded one of the largest clinical trials using PRP for hair growth and served as the chief editor for Platelet Rich Plasma (PRP) and Microneedling in Aesthetic Medicine. Earning a bachelor’s degree from Stanford University and medical doctorate from University of California San Francisco, Dr. Hausauer completed residency at New York University then an American Society for Dermatologic Surgery cosmetic surgery fellowship.

Leadership

Qing Yu Christina Weng, MD

Chief Medical Officer

Chief Medical Officer

Dr. Weng is the CMO of Pelage. She is a physician-scientist and entrepreneur, board-certified dermatologist, and Lecturer at Harvard Medical School. She is experienced in corporate startup strategy as Head of Business Development & Strategy at Kira Pharma and CSO and cofounder of Mymiel Skincare. She is on the Board of Directors for the Dermatology Innovation Forum and Dermatology Summit. Dr. Weng has an undergraduate degree from the California Institute of Technology, MD from Harvard, and she completed dermatology residency and fellowship at Harvard.

Leadership

Daniel Gil, PhD

Chief Executive Officer

Chief Executive Officer

Dr. Gil is the CEO of Pelage. He is also a Venture Partner with Visionary Ventures. Until 2018, Dr. Gil was a Vice President at Allergan, overseeing the research portfolio and early clinical development. His research contributed to development of 5 marketed drugs and he led 8 clinical development projects. He is an inventor on 70+ issued US patents and author on 45 peer-reviewed research articles. Dr. Gil has an undergraduate degree in Biology from Harvard University and a PhD in Pharmacology from the University of Pennsylvania.

Leadership

Michael Jung, PHD

Co-Founder

Co-Founder 
Professor, UCLA Chemistry & Biochemistry

Dr. Jung is a renowned Medicinal Chemist and co-founder of several successful startups. He is also co-inventor of two FDA approved drugs for prostate cancer (Xtandi & Erleada) with several drugs currently in clinical trials.

Leadership

Heather Christofk , PhD

Co-Founder

Co-Founder
Professor, UCLA Biological Chemistry

Dr. Christofk is a leader in the metabolism field with a research focus on how metabolism regulates cell state transitions. Her groundbreaking collaborative research with Dr. Lowry revealed that changes in metabolism can instruct hair follicle stem cell activation, forming the basis for the Pelage’s approach to treat hair loss. She is a Professor of Biological Chemistry at the David Geffen School of Medicine at UCLA and Associate Director of Basic and Translational Research at the UCLA Jonsson Comprehensive Cancer Center. She earned her bachelor’s degree from UCLA, her PhD from Harvard, and conducted postdoctoral research at UCSF before joining the faculty at UCLA in 2008.

Leadership

William Lowry, PhD

President & Co-Founder

President & Co-Founder
Professor, UCLA Molecular, Cell and Dev. Biology 

Dr. Lowry is a leader in the stem cell field with 20+ years of research experience resulting in the discovery that hair follicle stem cells can be activated by metabolic manipulation. His work has led to the creation of several startups including Pelage and Sardona, as well as other efforts under development.